CRE Detect and Protect: the Role of Local Health Departments

March 26, 2014





Agenda

- Featured speaker: Dr. Mike Vernon "Role of a Local Health Department in Investigating Outbreaks of CRE"
- XDRO registry overview
- LHD response to CRE calls
- CRE Detect and Protect Campaign

The opinions, viewpoints, and content presented in this webinar may not represent the position of the Illinois Department of Public Health

Role of a Local Health Department in Investigating Outbreaks of Carbapenem-Resistant Enterobacteriaceae (CRE)

Michael O. Vernon, DrPH Director, Communicable Disease Control Cook County Department of Public Health





Presentation Outline

- Background on antimicrobial resistance among Enterobacteriaceae
 - KPC versus NDM-producing organisms
- KPC outbreak investigation at a LTCF (2008)
- NDM outbreak investigation at an acute-care MC (2013)
 Timeline
 - LHD activities in outbreak response
 - Relationships between outbreak site, other HC facilities, and local, state and federal partners





Antibiotic Resistance Threats in the U.S., 2013



Untreatable and hard-to-treat infections from carbapenem-resistant Enterobacteriaceae (CRE) bacteria are on the rise among patients in medical facilities. CRE have become resistant to all or nearly all the antibiotics we have today. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection.

RESISTANCE OF CONCERN

- Some Enterobacteriaceae are resistant to nearly all antibiotics, including carbapenems, which are often considered the antibiotics of last resort.
- More than 9,000 healthcare-associated infections are caused by CRE each year.
- CDC laboratories have confirmed at least one type of CRE in healthcare facilities in 44 states.
- About 4% of U.S. short-stay hospitals had at least one patient with a serious CRE infection during the first half of 2012. About 18% of long-term acute care hospitals had one.

PUBLIC HEALTH THREA

An estimated 140,000 healthcare-associated Enterobacteriaceae infections occur in the United States each year; about 9,300 of these are caused by CRE. Up to half of all bloodstream infections caused by CRE result in death. Fortunately, bloodstream infections account for a minority of all healthcare-associated infections caused by Enterobacteriaceae. Each year, approximately 600 deaths result from infections caused by the two most common types of CRE, carbapenem-resistant *Klebsiella* spp. and carbapenem-resistant *E. coli*.

	Percentage of Enterobacteriaceae healthcare-associated infections resistant to carbapenems	Estimated number of infections	Estimated number of deaths attributed	
Carbapenem-Resistant <i>Klebsiella</i> spp.	11%	7,900	520	
Carbapenem-resistant E. coli	2%	1,400	90	

For more information about data methods and references, please see technical appendix.



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

CDC Report released: September 16, 2013

sease.

Background: Enterobacteriaceae

- Bacteria in the family Enterobacteriaceae are gram-negative rods
 - *E. coli* and *Klebsiella pneumoniae* are organisms in the Enterobacteriaceae family
 - Normal part of the gastrointestinal flora
 - Common cause of healthcare-associated infections





Background: Carbapenems

- β-lactam antibiotics have been used to treat infections caused by Enterobacteriaceae
- Carbapenems are a class of β-lactam antibiotics with a broad spectrum of antibacterial activity
 - Used as a last resort when other antibiotics are not available





Carbapenem-Resistant Enterobacteriaceae

- Resistance conferred by carbapenem-hydrolyzing
 β-lactamases
 - Two primary classes:
 - Class A: Carbapenemases, e.g., Klebsiella pneumoniae carbapenemases (KPC)
 - Class B: Metallo-β-lactamases (MBL)
 - New Delhi metallo- β-lactamases (NDM)
- Production of KPCs is the major mechanism
- Gene encoding resistance is present on plasmids





Why is Carbapenem Resistance a Public Health Problem?

- Significantly limits treatment options for lifethreatening infections
- No new drugs for gram-negative bacilli
- Emerging resistance mechanisms, carbapenemases are mobile
- Detection of carbapenemases and implementation of infection control practices are necessary to limit spread = "Detect & Protect"





KPC versus NDM

- KPC
- First reported in 2001 in NC; now in 47 states
- First identified in IL in 2007
- Common in Northern IL
- Increasingly found in healthcare institutions
- Long term care is a reservoir

- NDM
- First reported in US 2009
- First IL isolate in 2010
- 45 patients with NDM identified in IL in 2013
- 96 total cases in US
- Most dangerous CRE
- High mortality





Four Core Actions to Combat Spread of AR

- 1. Prevent infections from occurring and prevent AR bacteria from spreading
- 2. Track AR bacteria
- 3. Improve use of antibiotics
- 4. Promote development of new antibiotics and new diagnostic tests for AR bacteria





Outbreak #1: KPC-producing CRE at a LTCF

- 11/6/2008 CCDPH received a call from an astute IP at Hospital A that 3 residents admitted from the same LTCF had infections caused by CRE
 - All 3 cases had clinical CAUTIs
 - KPC was confirmed by the modified Hodge test
 - All cases were ventilator-dependent females with indwelling Foley catheters, multiple comorbidities and a history of long-term therapy with several antimicrobial agents





• 11/7/2008 – CCDPH called LTCF A to report culture results on the 3 residents admitted to Hospital A

The DON at LTCF A confirmed that:

- All 3 residents resided on the same floor at LTCF A reserved for ventilator-dependent pts
- LTCF A staff had <u>no knowledge of CRE or KPC</u>
- <u>No isolation precautions in place</u>
- <u>No IP on staff</u>; no contract with an IP consulting agency





- 11/7/2008 Hospital A started performing active surveillance cultures for CRE on all patients admitted from LTCF A
 - Perirectal cultures obtained on admission
 - 3 residents identified as CRE-colonized within 1 week
 - All 3 lived on the same floor at LTCF A that housed ventilator-dependent residents





- 11/12/2008 CD staff from CCDPH visited LTCF A to perform a walk-through survey, observe infection control practices, and make IC recommendations
 - 245-bed facility
 - 3rd floor used for individuals requiring skilled care
 - Hemodialysis unit in the lower level
 - DON responsible for infection control adherence
 - Major renovation project underway





Floor Plan of 3rd Floor -- LTCF A



Immediate Public Health Recommendations

- Contact precautions for residents infected or colonized with CRE (indefinitely)
- Cohort residents with CRE
- Use dedicated staff and equipment
- Maintain daily log of infected and colonized residents
- Communicate with CCDPH IP specialist daily
- Communicate with IP at Hospital A regarding each patient transfer





Public Health Actions

- All-staff education sessions at LTCF A for all three shifts
- Emphasis on infection prevention including:
 - Hand hygiene
 - Isolation precautions
 - Signage
 - Skin cleansing of residents 2% CHG
 - Environmental cleaning and disinfection





- 11/24/2008 CDC Epi-Aid assistance requested by CCDPH and IDPH
- 12/3/2008 Field investigation began (9 cases total)
- Objectives of CDC investigation:
 - Determine scope of the outbreak
 - Identify risk factors for infection and colonization with CRE
 - Identify possible sources of transmission
 - Recommend control measures to prevent additional cases





Components of Epi-Aid Investigation 12/4 – 12/16, 2008

- Active surveillance cultures at LTCF A to identify CRE-colonized patients
- Review charts for a case control study to examine risk factors among patients
- Observe infection control practices
- Record keeping & data analysis
- Daily group meetings to review findings and make plans for next steps





Spot Map of Resident Room Assignments and Case Status: Screening Cultures (12/4)



Case Control Study Findings

- Risk of CRE significantly increased by:
 - Having a urinary catheter: OR=21 (95%
 CI, 3.8-116)
- Receiving a carbapenem was more frequent among cases than control, but the difference was not statistically significant
 - -OR=2.5 (95% Cl, 0.7-9.0)





Summary of CRE-Positive Screening Culture Results

Point Prevalence —Incidence



Responsibilities of CCDPH

- Guidance on CP for residents in a LTC setting
 - Conditions for participation in group activities
 - Incontinence care
 - Need to maintain CP for asymptomatic (colonized) residents
 - Explanation of barrier precautions to family members
- Recommendations for CP in rooms with multiple residents (screens; HH; dedicated staff & equipment)
- Coordination of specimen collection & testing
- Coordination of communication and outbreak control activities among state and federal HDs, LTCF A and Hospital A

of Public Health Promoting health. Preventing disease. Protecting you.

Communication & Coordination Network: KPC Outbreak Investigation



Communication & Coordination Network: KPC Outbreak Investigation



Final Public Health Recommendations

- Designate an Infection Preventionist
- Staff education
- MDRO surveillance
- Antibiotic stewardship
- Limit device use
- Patient skin cleansing
- Environmental cleaning
- Report to CCDPH as often as necessary





Cook County Department of Public Health

Promoting health. Preventing disease.

Protecting you.

Outbreak #2: NDM-producing E. coli at an Acute Care Hospital

- CCDPH notified of 1st case in March 2013
- 5 cases identified through April 2013
- 1 case with matching PFGE from a Chicago hospital in May
- 3 more cases identified through July 2013
- Duodenoscope implicated and removed from service in June
- CDC Epi-Aid requested in August 2013







Outbreak Response Activities by Hospital A

- Timely notification
- Highly qualified & experienced IP team
- Lab capacity
- Internal measures:
 - Assessments
 - Screening
 - Interventions
 - Possible source identification





Objectives of the Epi-Aid Investigation

- Describe healthcare exposures of cases
- Identify sites of and risk factors for transmission
- **Review IC practices**
- Identify possible routes of transmission
- Investigate possible association between cases and procedures
- Conduct full and thorough epidemiologic analyses
- Recommend measures to prevent additional transmission





Activities Associated with the Epi-Aid Investigation

- Team of 3 EIS officers & 1 CSTE Fellow
- Information gathering -- chart abstractions, observations, HCP interviews
- Sampling (persons, environment) for lab analyses
- Shipment of specimens to CDC for molecular typing
 - Epidemiologic studies
 - Case control
 - Cohort
- Daily communication among outbreak investigation
 team

Case-Control Study

- Identify exposures that may contribute to NDM transmission by comparing confirmed cases (patients with NDM) with controls (patients without NDM)
- Controls were randomly selected from a list of individuals who were screened on Rehab Unit at Hospital A between 5/1 – 6/1
- 9 cases; 27 controls





Case-Control Study Results

Procedure	% Cases (N=9)	% Controls (N=27)	Odds Ratio	p-value
<mark>Duodenoscopy*</mark>	67	4	52.0	0.001
GI Suite	67	11	16.0	0.003
Antibiotics	89	56	6.4	0.10
Anesthesia	79	44	4.4	0.10
Endoscopy	22	11	2.3	0.41
Operating Room	56	41	1.8	0.44
СТ	79	74	1.2	0.82
MRI	56	52	1.2	0.85
Interventional radiology	22	30	0.7	0.67





Cook County Department of Public Health Promoting health. Preventing disease. *Protecting you.*

*Past 6 months

Surveillance Screening Cultures on Epi-linked Patients: March-July, 2013

Facility Type	# Screened
Hospital A	131
Other ACHs*	25
LTACH*	55
LTCF*	118
Total	329

PP surveys and screenings of epilinked patients conducted at 8 ACHs, 14 LTCFs, and 2 LTACHs *CCDPH coordinated sample collection and testing





Cook County Department of Public Health Promoting health. Preventing disease.

Protecting you.


Conclusions

- Largest known cluster of NDM-producing *E. coli* in the US (still ongoing; March 2013-present)
 - Lab detection key component of investigation
 - No Hx of hospitalization outside of the US
 - Cases highly related by PFGE, suggesting local transmission
 - **Biologic plausibility**
 - NDM-producing E. coli and KPC cultured from the elevator channel of the implicated endoscope after reprocessing





Summary of CCDPHs Involvement

- Consultation with outbreak facility
 - IC guidance & education to staff (primarily LTCFs)
- Coordination of communication linkages between STACHs, LTACHs, LTCFs, LHDs, IDPH, CDC
- Notification to State HD
- Request for Epi-Aid assistance (if necessary)
- Participation in epidemiologic and environmental investigation
- Coordination of specimen collection & testing
- Co-authorship on publication





CRE Control: What LTCFs can do

- Enforce CP for residents with draining wounds, diarrhea, indwelling devices, etc.)
- Closely monitor residents with incontinence and dementia
- Require use of gown, gloves, and performance of HH
 by visitors and family members when closely
 interacting with residents and their environment
- Educate ambulatory residents (w/o devices or draining wounds) about HH and <u>allow</u> participation in group activities





CRE Control: What Acute Care Hospitals can do

- Ask if patients have received medical care overseas
- Follow IC recommendations with every patient, using CP for patients with CRE
- Dedicate room, equipment, and staff to CRE patients
- Prescribe antibiotics wisely
- Remove temporary medical devices ASAP
- Assure manufacturer's recommendations are followed for cleaning & reprocessing of reusable devices ... e.g., endoscopes
- Consider ASC and empiric CP when necessary





Statewide Public Health Initiatives

- XDRO Registry: Effective Nov 1, 2013 all HC facilities and Labs in IL required to report CRE via the IDPH web portal
- **CRE Task Force:** Aim is to identify and develop actionable public health interventions
- Meeting Forums: TAG, NIPHC, HAI Advisory Council, LTC roundtable with representation by IP, ID, and micro lab directors





General CRE Recommendations

SEARCH

Utilize XDRO state registry to identify patients
Refer to CDC CRE toolkit online for more

information

Centers for Disease Control and Prevention CDC 24/7: Saving Lives. Protecting People.™

A-Z Index A B C D E F G H I J K L M N O P Q R S I U V W X Y Z #

Healthcare-associated Infections (HAIs)

Healthcare-associated Infections	Healthcare-associated Infections > Diseases and Organisms > Carbapenem-resistant Enterobacteriaceae (CRE)	Email page link
HAIs: The Burden	Recommend 22 Tweet 9 Chare	🐼 Get email updates
Monitoring HAIs	2012 CRE Toolkit - Guidance for Control of Carbapenem-	
Types of Infections	resistant Enterobacteriaceae (CRE)	🗹 Get email updates
Diseases and Organisms	Tesistant Enterobacteriaceae (CRE)	To receive email
Acinetobacter	Carbapenem-resistant Enterobacteriaceae (CRE) are a serious threat to public health. Infections with CRE are difficult, and in some cases impossible, to treat and have been associated with mortality rates	updates about this page, enter your email
Burkholderia cepacia	up to 50%(1). Due to the movement of patients throughout the healthcare system, if CRE are a	address:
Clostridium difficile	problem in one facility, then typically they are a problem in other facilities in the region as well. To	
Clostridium Sordellii	help protect patients and prevent transmission, CDC has released a CRE toolkit which expands on the 2009 CDC recommendations and continues to be updated as new information becomes available.	What's this? Submit
Carbapenem-resistant Enterobacteriaceae (CRE)	Table of Contents	
Tracking CRE	• Introduction	Contact Us:
Patients	Background	Centers for Disease Control and Prevention
Patient FAQ	• Definitions	1600 Clifton Rd Atlanta, GA 30333
General Information	Part 1: Facility-level CRE Prevention	300-CDC-INFO
Clinicians	Surveillance	(800-232-4636) TTY: (888) 232-6348
Clinician FAQ	Facility-level Prevention Strategies	Contact CDC-INFO
Facilities/Settings State Health	Core Measures for All Acute and Long-term Care Facilities. Guidance for Control of Carbapenem-resistant	
Departments	 Supplemental Measures for Healthcare Facilities 	and and
►CRE Toolkit	with CRE Transmission 2012 CRE Toolkit	
Introduction	 Recommendations for Facilities with No or Rare CRE 	CRE Sunty Department
Background	Summary of Prevention Strategies for Acute and	VITAL SIGNS c Health
Part 1: Facility-level CRE Prevention	Long-term Care Facilities Guidance for Control of Carbapenem-	ag health. Preventing disease
Supplemental Measures for Healthcare Facilities	Part 2: Regional CRE Prevention: Recommended Strategies for Health Department Implementation 2012 CRE Toolkit [PDF - 2.98 MB]	Vitalsigns' www.cde.gov/Halsigns
with CRE Transmission	Public Health Engagement	
n in n 1 1005	Regional Surveillance for CRE	

Acknowledgements

- Centers for Disease Control & Prevention (CDC)
 - Division of Healthcare Quality Promotion (DHQP)
- Illinois Department of Public Health (IDPH)
 - Office of Local Health Protection
- Chicago Department of Public Health (CDPH)
 - Communicable Disease Control
- DuPage County Health Department (DCHD)
 - Communicable Disease Control
- Staff affiliated with STACHs, LTACHs, and LTCFs involved in the outbreak investigations





XDRO Registry

Mandatory reporting to the eXtensively Drug www.xdro.org **R**esistant Organism registry began November 1, 2013 Amendment to the Control of Communicable Diseases Code (77 III. Adm. Code 690) Rules

https://www.xdro.org/img/MEMO_XDRO%20Registry_090413_Final.pdf

Extensively drug resistant organism



The XDRO registry is a product of collaboration between IDPH, Medical Research Analytics and Informatics Alliance (MRAIA), and the Chicago CDC Prevention Epicenter.

www.xdro.org

Carbapenem-resistant Enterobacteriaceae (CRE) are extremely drug resistant organisms (XDROs) that have few treatment options and high mortality rates. CRE at occreasingly detected among patients in Illin, DDULLXDDO

detected among patients in Illin DPH.XDROregistry@illinois.gov

In response to the CRE public health threat, the Illinois Department of Public Health (IDPH) has guided development an infection control tool called the XDRO registry. The purpose of the XDRO registry is two-fold:

- Improve CRE surveillance: The first CRE-positive culture per patient stay must be reported to the XDRO registry.
- 2. **Improve inter-facility communication:** Healthcare facilities can query the XDRO registry to see whether a patient has been previously reported as CRE-positive.

UPDATES

CRE are reportable to IDPH via the XDRO registry. Links: [IDPH letter to facilities, September 2013][Reporting rule]

To report CRE, you need a log-in to the IDPH portal

Existing INEDSS users: Your existing IDPH log-in will automatically give you access to XDRO registry New users: Go to the IDPH log-in page and sign up for INEDSS, which will give you access to the XDRO registry

XDRO registry orientation webinar [Slides][Recording]

CDC guidance on control of CRE: [The 2012 Toolkit]

As of November 1, 2013, the XDRO registry is open for CRE submissions and queries.

Login

Help

XDRO Registry

X / A Y

Why?

The XDRO registry addresses 2 critical gaps

Gap	XDRO registry
1. Need improved inter- facility communication	Allows for CRE information exchange
2. Need improved detection	Stores CRE surveillance data

XDRO Registry

1 1

Who?

N

XDRO registry: intended participants

All Illinois hospitals (including LTACHs) All Illinois intermediate and long-term care All Illinois laboratories

* Registration through IDPH web portal, request I-NEDSS/ XDRO application

https://wpur.dph.illinois.gov/WPUR

XDRO Registry

When?

N

XDRO Registry- When does it gets reported?

Report 1st CRE event per patient per encounter

within 7 days of lab confirmation

XDRO Registry

What?

M

XDRO Registry- What gets reported? (CRE surveillance definition)

Reporting facilities shall report CRE based on laboratory test results:

1. Molecular test (e.g., PCR) specific for carbapenemase OR

2. Phenotypic test (e.g., Modified Hodge) specific for carbapenemase production

OR

 Susceptibility test (for *E. coli* and *Klebsiella* species only): non-susceptible to ONE of the carbapenems (doripenem, meropenem, or imipenem) AND resistant to ALL third generation cephalosporins tested (ceftriaxone, cefotaxime, and ceftazidime).

What NOT to report to XDRO

- Pseudomonas species
- -- NOT an enterobacteriaceae
- Acinetobacter species
- -- NOT an enterobacteriaceae
- *E. coli* and *Klebsiella species* that are <u>only</u> resistant to ertapenem
- Isolates that are non-susceptible to ertapenem are likely not carbapenemase producers

What NOT to report to XDRO

Pseudom

Acir

-- NO⁻

• E. c

resis

- -- NOT av acteriacea
 - rcies

ae

- nterob
- d Klebsie. ertapenen.
- -- Isolate are likely no

to ertapenem producers

are <u>only</u>

Report Carbapenem-Resistant Enterobacteriaceae (CRE) isolates to XDRO registry at xdro.org

DO NOT REPORT TO REGISTRY: ESBL, VRE, MRSA, other non-CRE isolates



XDRO Registry

N.

How is XDRO different from I-NEDSS?



Comparison to I-NEDSS

I-NEDSS



*ELR: Electronic Laboratory Reporting

Comparison to I-NEDSS



XDRO Registry: aggregate data (as of 3/24/14)

XDRO registry

- Total number of reports (de-duplicated): 591
- Total number of unique cases identified: 508
- Number of unique cases since November 1st: 377
- Number of unique facilities that have logged in: 292
- Number of unique facilities that have submitted reports: 96
- Number of unique facilities that have ever queried: 77

XDRO Registry: aggregate data (as of 3/24/14)

Blood

Other

Rectal

Sputum Unrepor...

Wound/...

(screeni...

Body fluid



Trend, Last 12 Months



XDRO registry

XDRO Registry: accessing data

Facilities: through XDRO registry
 Must be approved by IDPH security

Health Departments: through
 I-NEDSS AVR (Business Objects Tool)
 Must sign user agreement form

Creating a Web Intelligence Document

🔏 SAP BusinessObjects InfoView - Windows Internet Explorer	x
G v I http://dph084tboe1/InfoViewApp/lis ▼ 4 × I I I Aboo!	•
<u>F</u> ile <u>E</u> dit <u>V</u> iew F <u>a</u> vorites <u>T</u> ools <u>H</u> elp	
🚖 Favorites 🛛 🚔 🔁 Suggested Sites 👻	
🖶 🗸 🞐 SAP Busines 🗙 🎉 Symantec Ente 🎼 🔹 📓 👻 🖃 🖶 👻 Page 👻 Safety 👻 Tools 👻 🍘)-
	_
SAP BUSINESSOBJECTS INFOVIEW SAPI	Busin
🍪 Home Document List Open 🖌 Send To 🕞 Dashboards 🔸 🛛 🛛 Help Preferences About Log C	Dut
T	×
📔 🖹 🛛 New 🛛 Add 🗸 Organize - Actions - 🛛 Search title -	
E All InfoView Page Layout itle A Last Run	
···· 🔛 My F 😔 Web Intelligence Document ase Demographic Information	
Inbox Analytic elect the disease or condition from the p	
🖻 🖻 Publi 🖄 Category ases Universe Report Starter	
H Folder	
INEDSS Reports	
E CD Reports	
Total: 2 objects	
Discussions	Ŧ
The list pane is update 🔹 🔩 Local intranet Protected Mode: Off 🛛 🖓 👻 🔍 100% 🤜	•

BusinessObjects InfoView - Windows Internet Explorer							
✓	· 49	×	😢 Yah	00!			_
<u>E</u> dit <u>V</u> iew F <u>a</u> vorites <u>T</u> ools <u>H</u> elp							
vorites 🛛 🚔 🔁 Suggested Sites 🔫							
P BusinessObjects InfoView		-	⊠ <u>-</u> ⊡	-	<u>P</u> age ▼	<u>S</u> afety	Tools Tools
P BUSINESSOBJECTS INFOVIEW						SAF	BusinessOb
ome Document List Open - Send To - Dashboards -				Help	Prefere	ences	About Lo
Intelligence Document - New Document							
TB Tuberculosis					Administ	rator	/INEDSS/1
Tetanus Historical Data					Administ	rator	/INEDSS/\
VPD Cases					Administ	rator	/INEDSS/\
VPD Hepatitis B and Delta					Administ	rator	/INEDSS/\
VPD Hepatitis Cases 1988-2004					Administ	rator	/INEDSS/\
VPD Historical Data					Administ	rator	/INEDSS/\
VPD Influenza					Administ	rator	/INEDSS/\
VPD Mumps					Administ	rator	/INEDSS/\
VPD Pediatric Influenza Death					Administ	rator	/INEDSS/\
VPD Pertussis					Administ	rator	/INEDSS/\
VPD Rash					Administ	rator	/INEDSS/\
VPD Tetanus					Administ	rator	/INEDSS/\
VPD Varicella					Administ	rator	/INEDSS/\
XDRO Registry					LSTUTLE	R	/XDRO
ssions							
Cocal	intrar	net P	rotected N	Mode: Off		@	• 🔍 100%

Accessing XDRO data

XDRO universe selected when creating a new Web Intelligence Document

AVR data fields that are currently available

SAP BUSINESSOBJECTS	INFOVIEW SAP Business Objects	
🍪 Home Document List Open 🗸	Send To + Dashboards + Help Preferences About Log C	ut
New Web Intelligence Document	۲	х
🗋 📕 🛛 🍊 🗐 📰 🗸 📴 Edit Query	🖹 Edit Report 🕄 🕲 🛛 🕲	Ŧ
🗄 📑 🖓 📰 💕 Add Query 🔗 🎟		
Data Properties	Result Objects	?
XDRO Registry XDRO Registry XDRO Registry	Facility Name Facility Site Code Patient MRN Date of Admission Report Date Status User Name Organism Name Culture Acquisition Date Specimen Source Mechanism of Resistance Molecular Test Phenotypic Test E. coli and Klebsiella ssp. Reason of Deletion Last, First First Name Last Name Maiden Name Gender Date of Birth Race Ethnicity	
Report Date Status User Name	Address Street City County State Zip Facility Name DPH Site Code Facility Address Case Count Patient Count	ţ
Oisplay by objects	Query Filters 📴 🎘 🕇	Ð
Display by hierarchies		*
🗗 Query 1	4 1	3

Data Elements

Category	Object	Description
Registry	Facility Name	Name of facility that the user reporting the case is affiliated
	Patient MRN	Medical Record Number
	Date of Admission	Date of admission or seen by facility
	Report Date	Date the case is reported in the XDRO
Culture	Organism Name	Organism identified (i.e. Enterobacter spp., Klebsiella pheumoniae)
	Culture Acquisition Date	Date the specimen was collected
	Specimen Source	Site of specimen collection (i.e. blood, body fluid, rectal, sputum, tissue, urine, wound)
	Mechanism of Resistance	For example: NDM-1, KPC
	Comment	Free text field with additional case report details, if provided
Patient Demographics	Includes the following	ng: name, gender, date of birth, race, ethnicity, address (street, city, county, state, Zip)
Lab/IDPH only Facility Info	Facility Name /Address	The facility that a lab is reporting on behalf of (i.e. long term care facility)
Measures	Case Count	Case count is based on unique ID in the database. Patients can have multiple cases.
	Patient Count	Patient Count is patient Medical Record Number

S Variable Editor	x	
Variable Definition]	
Name: Age		
Qualification: Dimension	_	
Type: Number		MAN
Formula:		
=(DaysBetween([Date of Birth];[Culture Acquisition Date]))/365	×	
Data Functions Operators		
Address Age City Comment County County County Culture Acquisition Date Date of Admission Date of Birth Connection Connection	E	
Description OK Cancel) Help	

X

Formula for creating Age from Date of Birth and Culture Acquisition Date

11 - 2

Sample AVR Report

			$\overline{\mathbf{V} \cdot \mathbf{V}}$					Δ
SAP BUSINESSOBJECTS INFO	OVIEW						SAP Business Ot	o bjects
🇞 Home Document List Open 🗸 Ser	nd To 👻 Dashboards 👻					Help	Preferences About I	Log Ou
XDR03								
🗅 🔡 🔹 ੱ M 📰 🕶 📅 Edit Query	🗎 Edit Report		🍣 Ref	fresh All 👻 🔒	🔨 👻 Track	h h H	晅 🌾 🔍 Drill 🛍 🧕] ?
: 🗟 💤 💤 🍬 🦻 🕲 🛆 🚢 🕘 🔻	- = A↓ - Σ - ■	- 🖷 + 🛅 + 🗓	🗎 📝 View Structure			1	100% 👻 Page 🕅 🖣 1	► H
· · · B Z]	U 🛕 - 🔌 - 🔟 🖽	• / • E E E	= ₌ P	Í 🔤 I 🛷 📄				
Data Temp., Map Prope., Input.,								
Data P								
Derraite Code								
 E. coli and Klebsiella ssp. Ethnicity 								
Facility Address	Facility Site Code	Case Count	Patient Count					
Facility Name(Query 1 (1))	0	1	1					
First Name	0049	3	3					
- 🖊 Gender	0083	2	2					
Last, First		1	2					
Maiden Name	0099		1					
Mechanism of Resistance	0134	2	2					
Molecular Test	0145	7	7					
Patient MRN(Query 1 (1))	0146	8	7					
Patient MRN(Query 1)	0147	1	1					
Phenotypic Test	0148	2	2					
🔎 Reason of Deletion	0150	6	6					
 Report Date Specimen Source 	0152	8	8					
State	0154	10	10					
🖉 Status	0155	9	9					
Street	0156	6	6					
→ XDRO Registry.Facility Name((+	0157	12	11					
4	۲ (^۱		11,					P.
Arranged by: Alphabetic order 🝷	📝 Report 1 📑 Repo	rt 2 📝 Report 1 (1)	📄 📄 Report 4	Report 5	Report 5 (1)	🖻 Report 7	4	1 Þ 🗉

Sample AVR graphics

I X



Matches pattern query

SAP BUSINESSOBJECTS IN	FOVIEW	SAP Business Objects
🍪 Home Document List Open 🗸 S	end To 👻 Dashboards 👻	Help Preferences About Log Ou
XDR03		∓ ×
🖹 📕 🗉 🍏 🚺 🕶 📴	Edit Report	🍣 Run Queries 🔻 🟋 🔺 🕘 🍘 🕇
🗄 🗔 😽 🔚 🞁 Add Query 🔗 🎟 📗		
Data Properties	Result Objects	▼ × 🕅
User Name Drganism Name Culture Acquisition E	Case Count Patient Count Facility Name Comment	
- Specimen Source	Query Filters	📈 X 🛱 🕾
Mechanism of Resist Molecular Test Phenotypic Test E. coli and Klebsiella	Comment Matches pattern 🗸 "Nursing Home A" Ę	
Display by objects		
Display by hierarchies		
🗊 Query 1 🧊 Query 1 (1)		4 ▷ 🗉
	Leat Defini	sch Distau March 26, 2014 11:10:47 AM GMT 05:00

Matches pattern query allow for free text searches by finding a string that matches a pattern Wildcards in pattern can include (*) to replace a set of characters or (?) to replace one character

Training Manual Location

SAP BUSINESSOBJECTS INFOVIEW				SAP Busine	ssObjects
🍪 Home Document List Open 🖌 Send To 🖌 Da	shboa	rds 🕶	Help Prefer	ences Abo	ut Log Out
					∓ ×
🔁 😂 🗞 + New 🔹 Add 👻 Organize 👻 Actions	•	Search title 👻	🔎 M	 ▲ 1 of 1 	▶ ▶
^{i⊟} All		Title *			Last Ri
🔤 My Favorites		AVR Formula Cheat Sheet			
"" 🔤 Inbox		Cheat Sheet on creating Formulas			
🖻 📴 Public Folders		AVR Hyperlink Formula			
🗐 🛄 INEDSS Reports	_				
📁 Aggregate Reports	N	Chapter 1: Running Canned Report			
···· 🖿 ArboReports	_	How to run a Canned Report.			
🖭 🛄 CD Reports		Chapter 2: Understanding Business Objects Organization and Fields			
🐃 🛅 Death Certificate Import Reports	-				
···· 🖿 ELC ELR Reports		Chapter 3: Report Building and Queries			
🖿 Hepatitis	-	This will teach users how to create ad hoc reports using simple queries.			
🔤 Hyperlink Reports		Chapter 4 sharing reports.			
···· 🛅 IDPH	R	This will teach users how to send reports to another users Business Objects "Inbox" and	I how to schedu	ile reports to	r
🛄 LHD Simple Reports		Chapter 5: Report Output and Presentation Styles			
Preparedness & OHP Performance Mer Definition of the second sec					
		Chapter 6: Manipulating Data			
	-	Teaches users how to apply functions and calculations to data.			
🖹 🔚 STD Reports	\sim	Chapter 7: Inserting New Reports and Queries and Changing Universes			
🕀 📠 TB Reports	_				
🖤 🗁 Training Materials	2	Chapter 8 Advanced AVR creating variables2_slh5			
🔤 VPD Reports					
🐃 🛄 ORS Reports		Old Version: Chapter 8 Advanced AVR creating variables			
🔤 Provider Reports	R	Descentation Obdes			
	~	Presentation Styles			
		How to create different Presentation Sytles.			
	<u>~</u>	Report Building and Simple Queries How to build simple reports and queries			
	₽	Sharing Reports			
	2~	How to Share Reports			
		•			
۰ III ا	•	III		Total: 14	- bis abs
When a call comes in...

	Anaerobic bottle is positive	Klebsiell	a pneum	oniae
		Kpneum]
	Antibiotic	MIC	INTRP]
	Amoxicillin/CA	>=32	R	1
	Ampicillin	>=32	R]
	Cefazolin	>=84	R	1
\langle	Ceftriaxone	>=64	R	
	Ciprofloxacin	>=4	R	
	ESBL	Neg	-	
	Gentamicin	8	ľ	
9	Imipenem	>=16	R	
	Levofloxacin	>=8	R	
	Piperacillin/tazobactam	>=128	R	
ľ	Tetracycline	4	S	
ĺ	Trimethoprim/Sulfa	>=320	R	
ŝ	-SUSCEPTIBLE I-INTERMEDIATE		R-RESISTANT	

 Confirm CRE: request actual lab reports

• Immediate infection control guidelines

 Further investigation

 Microbiology lookback (6-12 mos)

 Inter-facility communication

When a call comes in...







2012 CRE Toolkit

0.0



Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing *Enterobacteriaceae* in Acute Care Facilities



http://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5810a4.htm

CRE Toolkit

Summary Of Prevention Strategies For Acute And Long-Term Care Facilities

- Contact precaution guidelines
 Both acute care and long-term care settings
- Screening guidelines (e.g. epi-linked to CRE colonized or infected patients)
- In facilities with CRE transmission
 - Active surveillance guidelines (e.g. point prevalence rectal surveillance cultures on unit)
 - Patient and staff cohorting guidelines
 - Chlorhexidine bathing information

CRE Toolkit

 Also specific guidance for facilities that have rarely or never previously identified CRE Appendix B: General Approach to Carbapenem-resistant Enterobacteriaceae (CRE) Control In Facilities that Rarely or Have Not Identified CRE

New CRE-colonized or CRE-infected patient identified

Ų

- Notify appropriate personnel (i.e., clinical staff, infection prevention staff)
- Notify public health if indicated

ŀ

- Place patient on Contact Precautions in single room (if available)
- Reinforce hand hygiene and use of Contact Precautions on affected ward/unit
- Educate healthcare personnel about preventing CRE transmission

÷

- Screen epidemiologically-linked patient contacts (e.g., roommates) for CRE with at least stool, rectal, or peri-rectal cultures and/or consider point prevalence survey of affected unit
- Consider preemptive Contact Precautions of these patients pending results of screening cultures

÷

- If screening cultures or further clinical cultures identify additional CREcolonized or -infected patients, consider additional surveillance cultures of contacts or point prevalence surveys of affected units (if not already done)
- Consider cohorting patients and staff

٠

- · Ensure if patient transferred within the facility that precautions are continued
- Ensure if patient transferred to another facility CRE information is shared with accepting facility

Laboratory Samples

- In Illinois, CRE isolates OTHER than KPC are highest priority for further testing
- If phenotypic lab testing suggests enzyme other than KPC, lab should submit sample to IDPH
 - In absence of full testing, encourage sample submission from individuals with history of international medical care or epi-links to non-KPC CRE

Illinois CRE Detect and Protect



Infection prevention

Surveillance

Laboratory testing

Inter-facility communication

Antimicrobial stewardship

CRE Detect and Protect: IDPH Collaborators

Division of Patient Safety and Quality:

- Mary Driscoll, Division Chief
- Erica Runningdeer, HAI Coordinator
- Angela Tang & Robynn Leidig, CRE Project Directors
- Chinyere Alu, Antimicrobial Stewardship Project Director

Division of Infectious Diseases:

- Craig Conover, Senior Medical Advisor/ State Epidemiologist
- Allison Arwady, Epidemic Intelligence Service officer

Division of Laboratories:

- Matt Charles, Assistant Division Chief
- Roman Golash, Supervisor, Clinical Microbiology Section

Illinois CRE Task Force

<u>Purpose</u>

Guide CRE prevention and control efforts

<u>Leadership</u>

Dr. Stephanie Black (Chicago DPH) and Dr. Mary Hayden (Rush University Medical Center)

Membership

Facilities from across the spectrum of care (infectious disease doctors, infection preventionists, microbiologists, clinical staff), trade associations, state healthcare quality improvement organization, IDPH

CRE Task Force Members

1 1

- ACL Laboratories
- Advocate Lutheran General Hospital
- APIC- Central
- CDC Prevention Epicenter
- Chicago Department of Public Health
- Health Care Council of Illinois (HCCI) and Illinois Council on Long Term Care
- Illinois Hospital Association
- ISU/ Mennonite College of Nursing
- Kindred Healthcare
- Lee Manor Rehabilitation and Nursing Center
- Life Services Network
- Loyola University Medical Center

- Lutheran Life
- Metropolitan Chicago Healthcare Council
- NorthShore University Health
 System
- OSF Saint Francis Medical Center
- RML Specialty Hospital
- Saint Anthony Hospital
- Telligen
- The University of Chicago Medicine-Infection Control
- The University of Chicago Medicine-Microbiology
- UnityPoint Health Methodist



Campaign Sponsors

Association for Professionals in Infection Control and Epidemiology (APIC)

- Central IL, Chicago, Southern IL Chapters

CDC Chicago Prevention and Intervention Epicenter

Health Care Council of Illinois

Illinois Critical Access Hospital Network

Illinois Health Care Association

Illinois Hospital Association

Life Services Network

Metropolitan Chicago Healthcare Council

Nanosphere, Inc.

Telligen

The CRE Detect & Protect campaign is funded by an Affordable Care Act (ACA) award through the CDC



Campaign Sponsors (LHDs)

Cook County Dept of Public Health Chicago Dept of Public Health **DuPage County Health Dept** Henry County Health Dept Kane County Health Dept Kendall County Health Dept **Knox County Health Dept** McHenry County Dept of Health Schuyler County Health Dept St. Clair County Health Dept Whiteside County Health Dept



Pat Quinn, Governo LaMar Hasbrouck, MD, MPH, Director

Ave., Suite 700 • Chicago, IL 60603-6119 • www.idph.state.il.us

Illinois CRE Detect and Protect Campaign Sponsor Form

Background: In March 2014, the Illinois Department of Public Health (IDPH) will launch a statewide education campaign for carbapenem-resistant Enterobacteriaceae (CRE) prevention at acute care hospitals, long-term acute care hospitals, and long-term care facilities. IDPH will work with facilities and laboratories to adopt the Centers for Disease Control and Prevention strategy of detecting CRE and protecting patients through appropriate infection control and prevention measures.

We invite your organization to join the CRE Detect and Protect Campaign as a sponsor.

Basic sponsorship: As a sponsor, you agree to the following:

- Permit IDPH to use your name with campaign promotional efforts, such as press releases and listing your organization's name on the CRE campaign website.
- □ Assist in promoting the campaign. This can be accomplished through a written publication, prominent website posting, announcement at your organization's meeting or conference, or distributing campaign materials to other groups (e.g., hospitals and long-term care facilities).

Additional sponsorship

Provide other type of support not listed above. Please elaborate:

My signature below indicates that my organization agrees to be a sponsor of the IDPH CRE Detect and Protect Campaign.

Printed Name

Signature & Date

Title

Organization Name

Thank you for your partnership in this important initiative! Please email or fax the completed form to Angela Tang, CRE Project Director, and direct any questions to the same:

Angela.Tang@Illinois.gov Fax: 312-814-1953 Phone: 312-814-6226

Improving public health, one community at a time

printed on recycled pape

Facility Participants

Acute Care Hospitals: 88

Long-Term Care Facilities: 95

Long-Term Acute Care Hospitals: 3

Independent Labs: 1

(Signed up as of 3/21/14)



Illinois CRE Detect and Protect Campaign Participation Form – Healthcare Facilities and Independent Laboratories

CRE Detect and Protect

In March 2014, the Illinois Department of Public Health (IDPH) will launch a statewide education campaign to promote practices that prevent carbapenemresistant Enterobacteriaceae (CRE). We encourage acute care hospitals, longterm acute care hospitals, long-term care facilities, and independent or freestanding laboratories to sign up to participate in the campaign.

Why should my facility participate?

- CRE are extensively drug-resistant organisms (XDROs) that can spread quickly and have been increasingly detected among patients in Illinois.
- CRE prevention will result in better outcomes for your patients and reduced healthcare costs
- You will have the chance to learn from other healthcare facilities, labs, and CRE experts committed to this issue.
- Your facility will be listed on the campaign website in recognition of your commitment to improving
 patient care.

What are the requirements for participants?

Phone: 312-814-6226

- Attend CRE Detect and Protect webinars. This is a series of five webinars that will be led by
 infectious disease and infection prevention experts from March July 2014. Labs are asked to
 attend one webinar on lab testing and surveillance, but are welcome to attend other sessions.
- Obtain access and sign in to the XDRO registry, even if no CRE have been detected at the facility.

As an authorized executive, my signature below indicates that my facility agrees to be a participant of the IDPH CRE Detect and Protect Campaign.

Title	Facility Name
Facility type: Acute care hosp	oltai 🛛 Long-term acute care hospital
Skiled nursing i	
Please provide information for	the point-of-contact at your facility for the campaign:







Upcoming CRE Webinars (cont.)

Target Audience	Topics	Timeline (tentative)
Laboratorians	Reporting to XDRO, CRE testing guidelines	May
Infection prevention staff	Inter-facility communication	May
Infection prevention staff	CRE case studies, Outbreak response	June

Antimicrobial Stewardship



Vitalsio

Making Health Care Safer Antibiotic Rx in Hospitals: Proceed with Caution

More than half of all hospital patients receive an antibiotic.

Doctors in some hospitals prescribed 3 times as many antibiotics as doctors in other hospitals.



Reducing the use of high risk antibiotics by 30% can lower deadly diarrhea infections by 26%.

Antibiotics save lives, but poor prescribing practices are putting

patients at unnecessary risk for preventable allergic reactions, super-resistant infections, and deadly diarrhea. Errors in prescribing decisions also contribute to antibiotic resistance, making these drugs less likely to work in the future.

To protect patients and preserve the power of antibiotics, hospital CEOs/medical officers can:

- Adopt an antibiotic stewardship program that includes. at a minimum, this checklist:
- 1. Leadership commitment: Dedicate necessary human, financial, and IT resources.
- 2. Accountability: Appoint a single leader responsible for program outcomes. Physicians have proven successful in this role.
- 3. Drug expertise: Appoint a single pharmacist leader to support improved prescribing.
- 4. Act: Take at least one prescribing improvement action, such as requiring reassessment within 48 hours, to check drug choice, dose, and duration.
- 5. Track: Monitor prescribing and antibiotic resistance patterns.
- 6. Report: Regularly report to staff prescribing and resistance patterns, and steps to improve.
- 7. Educate: Offer education about antibiotic resistance and improving prescribing practices.
- Work with other health care facilities to prevent infections, transmission, and resistance.

→ See page 4 Want to learn more? Visit

www.cdc.gov/vitalsigns

National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion

Measuring Success of Antimicrobial Stewardship Efforts



When

Wednesday April 16, 2014 from 1:00 PM to 2:00 PM CDT Add to Calendar

Where

This is an online event.

Metrics applied to antimicrobial stewardship programs can help drive sustainable improvement within your organization. Join this webinar to learn how to identify pertinent data points and methods for antimicrobial use tracking.

Who Should Attend:

Pharmacists, Physicians, Nurses, Infection Prevention Personnel and Administrators interested in improving antimicrobial use and associated metrics at acute and long term care facilities.

Objectives:

- Compare and Contrast process and outcome metrics
- Identify necessary data points and methods for antimicrobial use tracking
- Identify pertinent outcome metrics when given a systematic stewardship intervention

Presenter:

Alan Gross, Pharm D., BCPS, Infectious Diseases Pharmacist at the University of Illinois Hospital and Health Sciences System and Clinical Assistant Professor at the University of Chicago, College of Pharmacy

Loria Pollack, M.D., MPH, Medical Officer at the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention

For additional information, contact Miriam Ovando, Project Assistant at Telligen.



This material was prepared by Telligen, the Medicare Quality Improvement Organization for Illinois, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy. 10SoW-IL-HAI-03/14-696

Contact information

- Direct XDRO questions/ comments to: DPH.XDROregistry@illinois.gov
- Direct CRE campaign questions/ comments to Robynn Leidig: Robynn.Leidig@illinois.gov, 312-814-1631 Angela Tang: Angela.Tang@illinois.gov, 312-814-6226



https://www.xdro.org/cre-campaign/index.html

